Intrinsiqq
Cullinan Therapeutics, Inc. logo

Cullinan Therapeutics, Inc. Insider Trading

CGEM

Compare
Last 12 months

Insiders sold $2.56M and bought nothing on the open market.

64% of the selling was scheduled in advance under 10b5-1 plans. The last open-market buy by an executive or director was in Jun 2022.

Net open-market
−$2.56M
0 buys · 25 sales
Under a 10b5-1 plan
64%
of the value sold
Insiders who bought / sold
0 / 5
executives and directors
Last open-market buy
Jun 2022
Jun 6, 2022

Get an email when CGEM's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

  • Nov 510b5-1 plan
    Jennifer Michaelson
    Chief Scientific Officer · sold 4,000 at $12.36
    49K
    2.5% of stake
  • Sep 810b5-1 plan
    Jennifer Michaelson
    Chief Scientific Officer · sold 8,000 at $21.57
    173K
    4.8% of stake
  • Aug 1310b5-1 plan
    Jennifer Michaelson
    Chief Scientific Officer · sold 30,000 at $20.26
    608K
    16% of stake
  • Jul 610b5-1 plan
    Jennifer Michaelson
    Chief Scientific Officer · sold 8,000 at $17.82
    143K
    4.7% of stake
  • May 510b5-1 plan
    Jennifer Michaelson
    Chief Scientific Officer · sold 8,000 at avg $14.62
    117K
    4.6% of stake
  • Mar 510b5-1 plan
    Jennifer Michaelson
    Chief Scientific Officer · sold 8,000 at $15.68
    125K
    4.5% of stake
  • Feb 2510b5-1 plan
    Jennifer Michaelson
    Chief Scientific Officer · sold 1,780 at $14.14
    25K
    1.0% of stake
  • Feb 23 – 2410b5-1 plan
    Jennifer Michaelson
    Chief Scientific Officer · sold 5,353 at avg $14.31
    77K
    2.9% of stake
  • Feb 24No plan
    Nadim Ahmed
    President and CEO · sold 13,515 at $14.47
    196K
    3.3% of stake
  • Feb 24No plan
    Jeffrey Alan Jones
    Chief Medical Officer · sold 4,582 at $14.47
    66K
    2.8% of stake
  • Feb 24No plan
    Jacquelyn L Sumer
    Chief Legal Officer · sold 3,601 at $14.47
    52K
    2.7% of stake
  • Feb 20No plan
    Mary Kay Fenton
    Chief Financial Officer · sold 4,398 at $13.62
    60K
    3.4% of stake
  • Feb 20No plan
    Jeffrey Alan Jones
    Chief Medical Officer · sold 4,982 at $13.62
    68K
    2.9% of stake
  • Feb 2010b5-1 plan
    Jennifer Michaelson
    Chief Scientific Officer · sold 11,742 at avg $14.08
    165K
    6.1% of stake
  • Feb 20No plan
    Jacquelyn L Sumer
    Chief Legal Officer · sold 3,742 at $13.62
    51K
    2.8% of stake
  • Feb 20No plan
    Nadim Ahmed
    President and CEO · sold 16,381 at $13.62
    223K
    3.9% of stake
  • Feb 12No plan
    Jennifer Michaelson
    Chief Scientific Officer · sold 416 at $12.03
    5K
    0.3% of stake
  • Jan 2210b5-1 plan
    Jennifer Michaelson
    Chief Scientific Officer · sold 4,000 at $12.30
    49K
    3.0% of stake
  • Dec 23, 2025No plan
    Nadim Ahmed
    President and CEO · sold 9,922 at $10.01
    99K
    2.3% of stake
  • Dec 19, 202510b5-1 plan
    Jennifer Michaelson
    Chief Scientific Officer · sold 1,345 at $10.01
    13K
    1.0% of stake
  • Dec 18, 2025No plan
    Jacquelyn L Sumer
    Chief Legal Officer · sold 3,480 at $9.67
    34K
    2.5% of stake
  • Dec 18, 2025No plan
    Jeffrey Alan Jones
    Chief Medical Officer · sold 4,632 at $9.67
    45K
    2.7% of stake
  • Dec 18, 2025No plan
    Jennifer Michaelson
    Chief Scientific Officer · sold 2,898 at $9.67
    28K
    2.1% of stake
  • Dec 12, 2025 – Dec 15, 202510b5-1 plan
    Jennifer Michaelson
    Chief Scientific Officer · sold 3,143 at avg $12.23
    38K
    2.2% of stake
  • Nov 24, 202510b5-1 plan
    Jennifer Michaelson
    Chief Scientific Officer · sold 4,000 at $12.30
    49K
    2.8% of stake
  • Oct 28, 2025
    Weston Nichols
    Large holder · bought 165,667 at $8.40
    $1.39M
    1.9% of stake
  • Oct 14, 2025 – Oct 17, 2025
    Lynx1 Capital Management LP
    Large holder · bought 248,749 at avg $8.46
    $2.1M
    1.5% of stake
  • Oct 8, 2025 – Oct 10, 2025
    Lynx1 Capital Management LP
    Large holder · bought 1,459,641 at avg $6.73
    $9.83M
    9.9% of stake
  • Feb 25, 2025No plan
    Jeffrey Alan Jones
    Chief Medical Officer · sold 4,895 at $8.53
    42K
    2.7% of stake
  • Feb 25, 2025No plan
    Jennifer Michaelson
    Chief Scientific Officer · sold 3,756 at $8.53
    32K
    2.6% of stake
  • Feb 25, 2025No plan
    Nadim Ahmed
    President and CEO · sold 12,529 at $8.53
    107K
    2.8% of stake
  • Feb 25, 2025No plan
    Jacquelyn L Sumer
    Chief Legal Officer · sold 3,756 at $8.53
    32K
    2.7% of stake
  • Jan 6, 202510b5-1 plan
    Jennifer Michaelson
    Chief Scientific Officer · sold 4,000 at $12.51
    50K
    4.0% of stake
  • Dec 24, 2024No plan
    Nadim Ahmed
    President and CEO · sold 8,400 at $11.87
    100K
    3.1% of stake
  • Dec 18, 2024No plan
    Jennifer Michaelson
    Chief Scientific Officer · sold 4,693 at $11.41
    54K
    4.5% of stake
  • Dec 18, 2024No plan
    Jeffrey Alan Jones
    Chief Medical Officer · sold 4,632 at $11.41
    53K
    3.9% of stake
  • Dec 18, 2024No plan
    Jacquelyn L Sumer
    Chief Legal Officer · sold 3,482 at $11.41
    40K
    3.7% of stake
  • Dec 12, 2024No plan
    Jennifer Michaelson
    Chief Scientific Officer · sold 3,489 at $12.52
    44K
    3.2% of stake
How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch CGEM, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with CGEM

CompareIntrinsic value
ACLXArcellx, Inc.
No recent price10
ACOGAlpha Cognition Inc.
$9.00+1.69%10
ALECAlector Inc.
$2.34+1.52%56
LCTXLineage Cell Therapeutics Inc.
$0.77-5.87%10
CRSPCrispr Therapeutics AG
$39.10+0.44%40
MGXMetagenomi, Inc.
$0.57-7.98%10
LENZLENZ Therapeutics, Inc.
$2.97-11.23%10
ELUTElutia Inc.
$0.89+8.54%20

Held by ETFs

CGEM is in 40 US ETFs. The largest of them, with CGEM's weight in each:

Spot a number that looks wrong? Check it in CGEM's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing CGEM

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.